FDA Clearance Tracker · P910056-S036
enVista One Piece Hydrophobic Acrylic Intraocular Lens
Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Jul 2, 2019
Approved
Time to decision
90 days
Received Apr 3, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P910056-S036
- Device name
- enVista One Piece Hydrophobic Acrylic Intraocular Lens
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Irvine, CA
- Received
- Apr 3, 2019
- Decided
- Jul 2, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P910056
Device type
- Device type
- intraocular lens (HQL)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval of the enVista® One Piece Hydrophobic Acrylic IOL, Model MX60ET, which includes a modification to the intraocular lens (IOL) material formulation of the approved parent lens, enVista® Model MX60T.
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
P240005 · Decided Oct 10, 2024 · 216 days after receipt
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
K192005 · Decided Oct 4, 2019 · 67 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.